{"id":"dep114","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Limited public information is available on DEP114's exact molecular mechanism. As a Phase 3 compound from EMS, it is likely a targeted immunotherapy or checkpoint modulator, but without disclosed target or mechanism details, the specific pathway of action cannot be reliably characterized.","oneSentence":"DEP114 is an investigational immunotherapeutic agent designed to modulate immune responses, though its precise mechanism remains proprietary.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:09:01.124Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06272409","phase":"PHASE3","title":"Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children.","status":"NOT_YET_RECRUITING","sponsor":"EMS","startDate":"2025-02-15","conditions":"Allergic Rhinitis","enrollment":318}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DEP114","genericName":"DEP114","companyName":"EMS","companyId":"ems","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}